Published in J Clin Endocrinol Metab on April 14, 2009
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project. | NCT02233322
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A (2011) 2.24
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol (2013) 1.89
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab (2011) 1.75
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant (2010) 1.52
Iron status and fibroblast growth factor-23 in Gambian children. Bone (2012) 1.38
Follow-up study of Gambian children with rickets-like bone deformities and elevated plasma FGF23: possible aetiological factors. Bone (2011) 1.26
Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab (2012) 1.21
Approach to the hypophosphatemic patient. J Clin Endocrinol Metab (2012) 1.16
FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol (2012) 1.06
Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials. Anemia (2012) 1.05
Recent advances in renal phosphate handling. Nat Rev Nephrol (2010) 1.04
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int (2016) 1.00
Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol (2014) 0.96
Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism. Int J Pediatr Endocrinol (2009) 0.93
Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia. Endocrinol Metab (Seoul) (2014) 0.92
Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol (2015) 0.91
Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol (2013) 0.91
The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant (2013) 0.90
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis (2015) 0.87
Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol (2016) 0.86
Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature. Case Rep Endocrinol (2014) 0.86
Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab (2011) 0.84
Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev Bras Hematol Hemoter (2015) 0.84
The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol (2012) 0.83
High dose intravenous iron, mineral homeostasis and intact FGF23 in normal and uremic rats. BMC Nephrol (2013) 0.82
Tumor-induced osteomalacia. Expert Rev Endocrinol Metab (2009) 0.82
Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis (2016) 0.80
High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol (2016) 0.79
The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev (2013) 0.79
Hypophosphatemic rickets: revealing novel control points for phosphate homeostasis. Curr Osteoporos Rep (2014) 0.78
En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review. World J Surg Oncol (2015) 0.78
Systemic Control of Bone Homeostasis by FGF23 Signaling. Curr Mol Biol Rep (2016) 0.77
Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation. Orphanet J Rare Dis (2014) 0.77
Fibroblast growth factor 23 and acute kidney injury. Pediatr Nephrol (2014) 0.77
Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial. BMC Nephrol (2016) 0.76
The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression. Bone Rep (2017) 0.75
Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther Adv Endocrinol Metab (2016) 0.75
What's new in FGF23 research? Bonekey Rep (2012) 0.75
Severe hypophosphataemia after intravenous iron administration. BMJ Case Rep (2017) 0.75
Disorders of phosphorus homeostasis. Curr Opin Endocrinol Diabetes Obes (2010) 0.75
Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients. Eur J Clin Nutr (2016) 0.75
Fibroblast Growth Factor-23-A Potential Uremic Toxin. Toxins (Basel) (2016) 0.75
A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report. Medicine (Baltimore) (2017) 0.75
Beneficial Effects of Oral Iron in Japanese Patients on Hemodialysis. Intern Med (2017) 0.75
Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol (2007) 2.60
Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA (2012) 2.27
Modeling the reactions of superoxide and myeloperoxidase in the neutrophil phagosome: implications for microbial killing. J Biol Chem (2006) 1.95
Breastfeeding protects against current asthma up to 6 years of age. J Pediatr (2012) 1.62
Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab (2008) 1.58
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol (2003) 1.55
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients. Am Heart J (2006) 1.52
Breastfeeding protects against adverse respiratory outcomes at 15 months of age. Matern Child Nutr (2009) 1.47
A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol (2006) 1.47
Impaired eye movements in post-concussion syndrome indicate suboptimal brain function beyond the influence of depression, malingering or intellectual ability. Brain (2009) 1.46
Subclinical thyrotoxicosis in an outpatient population - predictors of outcome. Clin Endocrinol (Oxf) (2011) 1.44
Use of autopsy in general surgery: a comparison of practice and opinion. ANZ J Surg (2007) 1.33
Gender differences in bipolar disorder: age of onset, course, comorbidity, and symptom presentation. Bipolar Disord (2005) 1.27
A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. J Hypertens (2003) 1.23
A common variant at chromosome 9P21.3 is associated with age of onset of coronary disease but not subsequent mortality. Circ Cardiovasc Genet (2010) 1.21
Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail (2013) 1.20
Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol (2009) 1.19
Genomic selection of reference genes for real-time PCR in human myocardium. BMC Med Genomics (2008) 1.19
Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem (2009) 1.17
Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol (2011) 1.17
Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 1.08
Eye movement and visuomotor arm movement deficits following mild closed head injury. Brain (2004) 1.08
Npr1-regulated gene pathways contributing to cardiac hypertrophy and fibrosis. J Mol Endocrinol (2007) 1.06
Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet Genomics (2005) 1.05
Motor deficits and recovery during the first year following mild closed head injury. Brain Inj (2006) 1.03
Hormone stability in human whole blood. Clin Biochem (2003) 1.01
Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J (2005) 0.96
Holmium laser bladder neck incision versus holmium enucleation of the prostate as outpatient procedures for prostates less than 40 grams: a randomized trial. J Urol (2005) 0.94
Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg (2004) 0.94
Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. Br J Psychiatry (2014) 0.92
The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med (2007) 0.91
Allergy after breast feeding: Study was not designed to test the hypothesis. BMJ (2007) 0.91
Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: a three year longitudinal study. Clin Biochem (2008) 0.91
Characterisation of proghrelin peptides in mammalian tissue and plasma. J Endocrinol (2007) 0.90
Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension (2006) 0.90
Prediction of cardiac rhythm 1 year following cardioversion for atrial fibrillation. N Z Med J (2011) 0.90
Mild head injury--a close relationship between motor function at 1 week post-injury and overall recovery at 3 and 6 months. J Neurol Sci (2007) 0.88
Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. Hypertension (2006) 0.88
Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease. Circ Cardiovasc Genet (2011) 0.87
Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust N Z J Psychiatry (2009) 0.87
An ELISA for plasma retinol-binding protein using monoclonal and polyclonal antibodies: plasma variation in normal and insulin resistant subjects. Clin Biochem (2007) 0.87
Plasma urocortin 1 in human heart failure. Circ Heart Fail (2009) 0.86
Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit (2007) 0.86
Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol (2008) 0.85
Endogenous urocortins reduce vascular tone and renin-aldosterone/endothelin activity in experimental heart failure. Eur Heart J (2005) 0.83
Responses to dehydration in the one-humped camel and effects of blocking the renin-angiotensin system. PLoS One (2012) 0.83
Effectiveness of an antagonist to gonadotrophin releasing hormone on the FSH and LH response to GnRH in perifused equine pituitary cells, and in seasonally acyclic mares. Anim Reprod Sci (2002) 0.82
Recovery in the first year after mild head injury: divergence of symptom status and self-perceived quality of life. J Rehabil Med (2007) 0.82
The impact of learning environment disruption on medical student performance. Med Educ (2013) 0.81
Plasma corticotropin-releasing hormone and unconjugated estriol in human pregnancy: gestational patterns and ability to predict preterm delivery. Am J Obstet Gynecol (2002) 0.81
Variability in measurements of blood glucose response to foods in human subjects is not reduced after a standard breakfast. Nutr Res (2009) 0.78
Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. Am Heart J (2008) 0.78
ANP and BNP responses to dehydration in the one-humped camel and effects of blocking the renin-angiotensin system. PLoS One (2013) 0.78
Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Clin Sci (Lond) (2004) 0.78
Ile164 variant of beta2-adrenoceptor does not influence outcome in heart failure but may interact with beta blocker treatment. Eur J Heart Fail (2008) 0.78
The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction. Cardiovasc Diabetol (2009) 0.78
Biomarker-guided treatment of heart failure: still waiting for a definitive answer. J Am Coll Cardiol (2010) 0.77
Cross-reactivities of macroprolactin and big-prolactin in three commercial immunoassays for prolactin: a chromatographic analysis. Clin Biochem (2007) 0.77
CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients. Clin Exp Pharmacol Physiol (2009) 0.77
Eosinophils and eosinophilic cationic protein in induced sputum and blood: effects of budesonide and terbutaline treatment. Ann Allergy Asthma Immunol (2002) 0.77
Production, composition and toxicology studies of Enzogenol® Pinus radiata bark extract. Food Chem Toxicol (2012) 0.77
Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord (2006) 0.76
Absence of a NPR-A gene functional deletion allele in a postmyocardial infarction cohort from New Zealand. Circ Res (2004) 0.76
Ovine forkhead box class O 3 (FOXO3) gene variation and its association with lifespan. Mol Biol Rep (2013) 0.76
AMPD1 gene polymorphism and survival in patients with stable congestive heart failure. Am Heart J (2007) 0.75
Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay. Clin Biochem (2006) 0.75
Is late-night salivary cortisol a better screening test for possible cortisol excess than standard screening tests in obese patients with Type 2 diabetes? N Z Med J (2012) 0.75
C-type natriuretic peptide forms in adult hyperthyroidism: correlation with thyroid hormones and markers of bone turnover. Clin Endocrinol (Oxf) (2012) 0.75
The Outcomes and Patterns of Treatment Failure After Surgery for Locally Recurrent Rectal Cancer. Ann Surg (2016) 0.75
A glucose reference curve is the optimum method to determine the glycemic glucose equivalent values of foods in humans. Nutr Res (2008) 0.75
Four cases of autosomal dominant hypocalcaemia with hypercalciuria including two with novel mutations in the calcium-sensing receptor gene. Ann Clin Biochem (2011) 0.75